Profile data is unavailable for this security.
About the company
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
- Revenue in USD (TTM)112.91m
- Net income in USD-61.67m
- Incorporated2012
- Employees266.00
- LocationWAVE Life Sciences Ltd7 Straits View#12-00, Marina One East Tower 018936SingaporeSGP
- Phone+65 62363388
- Websitehttps://www.wavelifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| National Research Corporation | 147.42m | 30.36m | 740.20m | 435.00 | 25.01 | 20.04 | 20.38 | 5.02 | 1.24 | 1.24 | 6.02 | 1.55 | 1.16 | -- | 11.53 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.55 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| ALX Oncology Holdings Inc | 0.00 | -166.20m | 740.34m | 74.00 | -- | 4.35 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 745.27m | 1.92k | 56.64 | 2.76 | 15.30 | 0.7456 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 752.21m | 53.00 | -- | 2.02 | -- | 233.31 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Humacyte Inc | 0.00 | -105.70m | 753.80m | 183.00 | -- | 28.82 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Wave Life Sciences Ltd | 112.91m | -61.67m | 765.71m | 266.00 | -- | 30.16 | -- | 6.78 | -0.5152 | -0.5152 | 0.9985 | 0.2719 | 0.4494 | -- | -- | 424,488.70 | -24.54 | -56.98 | -60.43 | -102.38 | -- | -- | -54.61 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Praxis Precision Medicines Inc | 2.20m | -125.38m | 776.52m | 82.00 | -- | 2.62 | -- | 353.77 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
| Hillevax Inc | 0.00 | -143.51m | 787.58m | 90.00 | -- | 3.25 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
| Regenxbio Inc | 86.73m | -260.15m | 787.60m | 344.00 | -- | 2.01 | -- | 9.08 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Disc Medicine Inc | 0.00 | -80.60m | 795.54m | 74.00 | -- | 2.35 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 802.03m | 180.00 | -- | 3.04 | -- | 6.44 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 803.48m | 140.00 | -- | 3.04 | -- | 21.58 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -98.15m | 803.91m | 116.00 | -- | 2.08 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 804.43m | 50.00 | -- | 2.56 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Data as of May 20 2024. Currency figures normalised to WAVE Life Sciences Ltd's reporting currency: US Dollar USD
52.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Mar 2024 | 18.20m | 14.89% |
| Maverick Capital Ltd.as of 31 Mar 2024 | 7.69m | 6.29% |
| M28 Capital Management LPas of 31 Mar 2024 | 7.00m | 5.72% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.80m | 4.74% |
| 683 Capital Management LLCas of 31 Mar 2024 | 5.35m | 4.38% |
| Adage Capital Management LPas of 31 Mar 2024 | 5.20m | 4.25% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 4.09m | 3.35% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 4.05m | 3.31% |
| Kynam Capital Management LPas of 31 Mar 2024 | 3.93m | 3.22% |
| PRIMECAP Management Co.as of 31 Mar 2024 | 2.88m | 2.35% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
